# NCT03215511 (NCT03215511)

> A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer

No report yet. It can be ordered.

- Drugs tested: selitrectinib
- Indication: previously treated NTRK fusion-positive solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03215511
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Bayer
- Conditions: Solid Tumors Harboring NTRK Fusion
- Interventions: Selitrectinib (BAY2731954)
- Enrollment: 81
- Primary outcome: Maximum tolerated dose (MTD)
- Primary outcome: Recommended dose

## Indexed commentary on NCT03215511 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03215511